# DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
> **ANDA219199** · Abbreviated New Drug Application (Generic) · Sponsor: ALEMBIC · Approved 2025-06-27
## Drug
- **FDA Application Number:** ANDA219199
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
- **Generic name:** DOXORUBICIN HYDROCHLORIDE
- **Active ingredients:** DOXORUBICIN HYDROCHLORIDE
- **Dosage form:** INJECTABLE, LIPOSOMAL
- **Route:** INJECTION
- **Marketing status:** Prescription
- **Sponsor:** ALEMBIC
- **Manufacturer:** Alembic Pharmaceuticals Limited
- **First approval:** 2025-06-27
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219199)
---
*AI Analytics · CC0 1.0*